Compare Merck & Co., Inc. (MRK) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs D Wave Quantum Inc — how do they compare? Merck & Co., Inc. trades at $133.65 (market cap $321.77B), while D Wave Quantum Inc trades at $20.72 (market cap $7.53B). The key difference: Merck & Co., Inc. is far larger — about 42.7× D Wave Quantum Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.
| MRK | QBTS | |
|---|---|---|
Market Cap | $321.77B | $7.53B |
Sector | Health | Technology |
52-Week High | $131.84 | $44.78 |
52-Week Low | $77.60 | $12.98 |
Enterprise Value | $368.53B | $7.04B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
D-Wave Quantum (QBTS) trades at $20.57, up 1.86% on the day, with a bearish technical signal despite unanimous analyst buy ratings. The stock exhibits extreme valuation metrics, including a P/S ratio of 583.84, while fundamentals show deep losses with a net income margin of -2001.59% in 2026. Recent Q2 2026 earnings missed revenue estimates but highlighted a 1120% surge in bookings, per Barrons on August 6, 2026.
The outlook hinges on commercial adoption of quantum computing, offering speculative upside with a consensus price target of $38.29, but high execution risks and cash burn pose significant threats to shareholder value amid volatile sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
